Key Highlights

  • Lilly slipped with a health care sector that finished second-worst in the S&P 500.
  • No company-specific catalyst for Lilly was confirmed.
  • Merck, Johnson and Johnson, Pfizer and Novo Nordisk also declined.
  • Only energy fared worse than health care among the 11 sectors.

Pulled down by the sector

Eli Lilly (NYSE:LLY) slipped during Wednesday's session, moving with a health care sector that finished as the second-worst performer in the S&P 500. No company-specific catalyst for Lilly was confirmed; the stock appeared to fall with its sector.

Other large drugmakers also moved lower. Merck (NYSE:MRK), Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) all declined, as did Novo Nordisk, Lilly's chief rival in obesity and diabetes treatments. Only energy fared worse than health care among the S&P 500's 11 sectors.

The broader market was mixed. The S&P 500 slipped 16.90 points to 7,323.63, its fifth straight loss and its longest losing streak since June. The Dow Jones Industrial Average fell 561.25 points to 50,198.17, with health care pushing it to its session low. The Nasdaq Composite rose 101.50 points to 24,429.88.

The insurer shock

The biggest force behind health care's slump was a selloff in health insurers, not drugmakers. Managed-care stocks fell for a second straight day after the Centers for Medicare & Medicaid Services proposed a rule on Monday that would broaden audits of Medicare Advantage plans. Humana (NYSE:HUM) was the S&P 500's worst performer, and UnitedHealth Group (NYSE:UNH) was the Dow's biggest drag.

The proposal, known as CRUSH, would let CMS extrapolate audit findings from a sample of medical records to an entire Medicare Advantage contract, starting with payment year 2018. CMS estimates it could save about $90 billion over 10 years. The rule is not final, and comments are due January 19, 2027.

That proposal targets insurers' payments rather than drug pricing. But when one large slice of a sector sells off hard, sector-tracking funds and broader health care portfolios can weigh on other members of the group, including pharmaceutical companies with no direct link to the news.

Lilly's place in the market

Lilly has become one of the most valuable health care companies in the world on the strength of its incretin-based drugs, including Mounjaro for type 2 diabetes and Zepbound for weight loss. It also sells treatments in oncology, immunology and neuroscience, including the Alzheimer's drug Kisunla.

Because of its size, Lilly carries heavy weight in health care indexes and funds, so it tends to feel sector-wide flows. Its shares are also closely tied to expectations for Demand in the obesity market, where competition, pricing and insurance coverage remain the central debates.

Rates and risk appetite

The macro backdrop was hawkish. Minutes from the Federal Reserve's October meeting showed "almost all participants judged that, under their baseline outlooks for Inflation and the labor market," further increases in the federal funds rate "would likely be appropriate." The Fed held rates steady in October, with Lisa Cook and Beth Hammack dissenting in favor of a hike.

Governor Christopher Waller said, "I'm very, very concerned about inflation. It's kind of headed in the wrong direction, and it's spreading out." Investor sentiment remained weak, with A widely followed Fear and Greed index at 25, in "Extreme Fear" territory.

Obesity Drug Updates Remain Lilly's Key Catalyst

Without company news, Lilly's next moves may depend on whether the insurer selloff spreads further or fades. Investors will watch for any developments on the CMS proposal, as well as industry commentary on Medicare policy more broadly.

For Lilly specifically, updates on obesity drug supply, pricing and coverage remain key. On the macro front, Thursday brings weekly jobless claims and remarks from Fed officials Jefferson, Goolsbee, Barkin and Barr, ahead of the Fed's December 8 to 9 meeting.